Atezolizumab-induced bilateral anterior uveitis: A case report

Tsuyoshi Mito; Shun Takeda; Nozomu Motono; Hiroshi Sasaki

doi:10.1016/j.ajoc.2021.101205

Atezolizumab-induced bilateral anterior uveitis: A case report

Am J Ophthalmol Case Rep. 2021 Sep 14:24:101205. doi: 10.1016/j.ajoc.2021.101205. eCollection 2021 Dec.

Authors

Tsuyoshi Mito¹, Shun Takeda¹, Nozomu Motono², Hiroshi Sasaki¹

Affiliations

¹ Department of Ophthalmology, Kanazawa Medical University, Japan.
² Department of Thoracic Surgery, Kanazawa Medical University, Japan.

Abstract

Purpose: To report a case of bilateral anterior uveitis undergoing atezolizumab treatment for advanced non-small cell lung cancer (NSCLC).

Observations: A 64-year-old man was receiving atezolizumab for metastatic programmed cell death ligand 1 (PD-L1) positive NSCLC as first line therapy. Three weeks after first atezolizumab administration, he complained of blurry vision in both eyes and was referred to our clinic. At initial presentation, slit lamp examination revealed bilateral Descemet membrane folds, fine keratic precipitates, and anterior chamber cells 2+. Dilated fundus examination showed no abnormal findings. A complete laboratory evaluation ruled out infectious or autoimmune causes of the uveitis and he was diagnosed with uveitis caused by atezolizumab. Atezolizumab was suspended, administration of topical corticosteroid was initiated, and the anterior uveitis was resolved within one month.

Conclusion and importance: This is the first case report of bilateral anterior uveitis associated with atezolizumab and that PD-1 and PD-L1 inhibitors cause uveitis.

Keywords: Anterior uveitis; Atezolizumab; Immune-related adverse events (irAEs); PD-L1 inhibitor.

Publication types

Case Reports